Scarica l'app Stockscreener
3.75
11.61%
0.39
Precedente Chiudi:
$3.36
Aprire:
$3.39
Volume 24 ore:
578.16K
Relative Volume:
0.68
Capitalizzazione di mercato:
$116.21M
Reddito:
-
Utile/perdita netta:
$-21.24M
Rapporto P/E:
-4.4755
EPS:
-0.8379
Flusso di cassa netto:
$-22.47M
1 W Prestazione:
+7.76%
1M Prestazione:
+3.31%
6M Prestazione:
+46.48%
1 anno Prestazione:
-37.40%
Intervallo 1D:
$3.3808
$3.77
Intervallo di 1 settimana:
$3.28
$3.77
Portata 52W:
$1.14
$7.11
Skye Bioscience Inc Stock (SKYE) Company Profile
Nome
Skye Bioscience Inc
Settore
Industria
Telefono
(858) 410-0266
Indirizzo
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Confronta SKYE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
1.40 | 2.19B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.45 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.41 | 111.01M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.3762 | 672.88M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.1699 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-15 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2024-09-30 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-09 | Iniziato | Craig Hallum | Buy |
| 2024-05-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-04-12 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Skye Bioscience Inc Borsa (SKYE) Ultime notizie
Is Skye Bioscience Inc. vulnerable to short sellers2025 Market WrapUp & AI Based Trade Execution Alerts - khodrobank.com
Is Skye Bioscience Inc.’s growth already priced inQuarterly Market Summary & Daily Chart Pattern Signals - khodrobank.com
What indicators show strength in Skye Bioscience Inc.July 2025 Setups & Safe Capital Growth Stock Tips - Newser
Can Skye Bioscience Inc. hit a new high this monthStop Loss & Weekly Sector Rotation Insights - Newser
How hedge fund analytics apply to Skye Bioscience Inc. stockEarnings Performance Report & Weekly Stock Performance Updates - Newser
Should you hold or exit Skye Bioscience Inc. now2025 Market Trends & Verified Entry Point Signals - Newser
Sentiment analysis tools applied to Skye Bioscience Inc.July 2025 Short Interest & Safe Capital Growth Stock Tips - Newser
Is Skye Bioscience Inc. stock bottoming out2025 Macro Impact & Risk Adjusted Buy/Sell Alerts - Newser
Analyzing drawdowns of Skye Bioscience Inc. with statistical toolsJuly 2025 Decliners & Low Drawdown Investment Strategies - Newser
Real time alert setup for Skye Bioscience Inc. performanceTrade Volume Report & High Return Stock Watch Alerts - Newser
What’s the beta of Skye Bioscience Inc. stockJuly 2025 Trade Ideas & AI Based Buy/Sell Signal Reports - khodrobank.com
Chart based analysis of Skye Bioscience Inc. trendsTrade Risk Assessment & Free High Return Stock Watch Alerts - Newser
Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study - GlobeNewswire
Sector ETF performance correlation with Skye Bioscience Inc.Quarterly Profit Report & Real-Time Buy Signal Notifications - Newser
Is Skye Bioscience Inc. stock poised for growthJuly 2025 Final Week & Reliable Volume Spike Trade Alerts - Newser
Using AI based signals to follow Skye Bioscience Inc.July 2025 Price Swings & Expert Curated Trade Setup Alerts - Newser
Volume spikes in Skye Bioscience Inc. stock – what they meanMarket Activity Recap & Entry Point Confirmation Signals - Newser
Is Skye Bioscience Inc. stock entering bullish territoryDip Buying & Free Fast Entry Momentum Trade Alerts - Newser
Custom watchlist performance reports with Skye Bioscience Inc.Quarterly Portfolio Report & Smart Money Movement Alerts - Newser
What does recent volatility data suggest for Skye Bioscience Inc.July 2025 Retail & Free Safe Entry Trade Signal Reports - Newser
Can Skye Bioscience Inc. maintain its current growth rateJuly 2025 Review & Risk Managed Trade Strategies - khodrobank.com
What’s the profit margin of Skye Bioscience Inc.Market Growth Summary & Weekly Market Pulse Updates - khodrobank.com
Published on: 2025-09-02 07:19:02 - Newser
Novel Obesity Drug Combined with Wegovy: Skye Completes Phase 2a Trial with 52-Week Extension Study - Stock Titan
Candlestick signals on Skye Bioscience Inc. stock todayWeekly Profit Recap & Real-Time Stock Price Movement Reports - Newser
How do insiders feel about Skye Bioscience Inc.Market Activity Report & AI Enhanced Trading Alerts - khodrobank.com
What are the analyst revisions for Skye Bioscience Inc.Is KNSL stock a good investment in YEAR2025 Geopolitical Influence & Advanced Technical Signal Analysis - khodrobank.com
Multi asset correlation models including Skye Bioscience Inc.Weekly Trade Recap & Daily Profit Maximizing Trade Tips - Newser
Skye Bioscience Inc. Shows Risk Reward Favoring Upside getLinesFromResByArray error: size == 0 - news-j.co.kr
Will earnings trigger a reversal in Skye Bioscience Inc.July 2025 Snapshot & Free Real-Time Market Sentiment Alerts - Newser
Will Skye Bioscience Inc. benefit from macro trendsJuly 2025 Setups & Detailed Earnings Play Strategies - Newser
Is Skye Bioscience Inc. building a consolidation baseJuly 2025 Snapshot & Capital Efficient Trading Techniques - Newser
Skye Bioscience Inc Azioni (SKYE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Skye Bioscience Inc Azioni (SKYE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schwab Andrew J. | Director |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 22 '25 |
Sale |
3.42 |
170,449 |
582,936 |
57,493 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
| Diep Tuan Tu | Chief Development Officer |
Nov 18 '24 |
Sale |
4.99 |
19,489 |
97,250 |
82,259 |
| Diep Tuan Tu | Chief Development Officer |
Nov 15 '24 |
Sale |
5.55 |
85 |
472 |
101,748 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 18 '24 |
Sale |
4.99 |
43,206 |
215,598 |
166,342 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 15 '24 |
Sale |
5.55 |
190 |
1,054 |
209,548 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 18 '24 |
Sale |
4.99 |
82,546 |
411,905 |
329,823 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 15 '24 |
Sale |
5.55 |
364 |
2,020 |
412,369 |
| Grayson Paul A. | Director |
Nov 18 '24 |
Sale |
4.99 |
86,244 |
430,358 |
259,701 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):